FYI now sent: FOI 24/242 following on from FOI 23/996 Internal Review

MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>
Fri 08/03/2024 18:28
To:FOILicensing <FOILicensing@mhra.gov.uk>
Cc:MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

From: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>
Sent: 08 March 2024 14:02
To: [redacted]
Subject: RE: FOI 24/242 following on from FOI 23/996 Internal Review

FOI 24/242

RE: Varoxpaxar

Dear [redacted]

Thank you for your email dated 1st March 2024, which we have given the reference number: FOI 24/242.

Following receipt of the internal review decision, you have asked us:

"can you even clarify if varoxpaxar has already been authorised for other uses? Or is this information not available either?"

As indicated in our previous correspondence, we confirm that there are no medicinal products currently authorised by MHRA that contain the active ingredient vorapaxar.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely,
MHRA Customer Service Team

From: [redacted]
Sent: Friday, March 1, 2024 4:23 PM